Search

everythinglearnresearchcommunity

for

Search:↓

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

COVID-19 vaccines can cause minor skin reactions, including those related to Bullous Pemphigoid, but these usually resolve on their own.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Gene therapy in mice increased lifespan and improved health without causing cancer.

Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Tocilizumab might be an effective treatment for COVID-19.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Flexible bioelectronics show promise in non-invasive cancer detection and treatment but need improvements in stability and effectiveness.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

BioPlex-11 improves DNA profiling from telogen hair roots in forensic work.

The FDA rejected a testosterone drug again due to safety concerns.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

The new fluoroquinolone effectively fights certain bacteria.

Electric pulses can effectively activate platelets and release growth factors, offering a better alternative to traditional methods.

Exprecell™ is as effective as traditional methods but produces more f-PRF and is simpler to use.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.

Compound 6 is a promising candidate for better wound healing.